Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer

[Business Wire] – Exelixis, Inc. announced that the Independent Data Monitoring Committee notified the company today that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed more

View todays social media effects on EXEL

View the latest stocks trending across Twitter. Click to view dashboard

See who Exelixis is hiring next, click here to view